8-K/A: ABVC BioPharma Amends Convertible Note with Lind Global Fund II, LP, Introducing Floor Price and Cash Payment Mechanism

ABVC BioPharma amended its convertible note agreement with Lind Global Fund II, LP, establishing a floor price for conversion and a cash payment mechanism under certain conditions.

Summary

• ABVC BioPharma amended its securities purchase agreement with Lind Global Fund II, LP, regarding a $1,000,000 convertible note issued on January 17, 2024.
• The amendment introduces a floor price of $1.00 for the conversion of the note into common stock.
• If the conversion price is determined to be the floor price, ABVC BioPharma will also make a cash payment to Lind based on a specific formula.
• The formula for the cash payment is (A-B) x C, where A is the number of shares that would be issued at 90% of the lowest VWAP, B is the number of shares issued at the floor price, and C is the VWAP on the conversion date.
• The initial shareholder meeting required under the Securities Purchase Agreement has been extended by one month to April 17, 2024.

Sentiment

Score: 4

Explanation: The amendment introduces a cash payment obligation, which is a negative, and the delay of the shareholder meeting is also a negative. The floor price provides some certainty, but the overall sentiment is slightly negative due to the potential financial burden.

Positives

• The amendment provides clarity on the minimum conversion price for the note.
• The extension of the shareholder meeting deadline provides additional time for ABVC to prepare.

Negatives

• The cash payment mechanism could potentially increase ABVC's cash outflow if the conversion price reaches the floor price.
• The need for an amendment suggests potential issues with the original agreement.

Risks

• The cash payment obligation could strain ABVC's finances if the stock price declines significantly.
• The conversion of the note could dilute existing shareholders' equity.
• The floor price of $1.00 could be reached if the stock price declines significantly.

Future Outlook

The amendment provides a framework for the conversion of the note, but the actual impact will depend on ABVC's stock price and the timing of any conversions. The cash payment mechanism adds a layer of complexity and potential cost.

Management Comments

• Uttam Patil, Chief Executive Officer of ABVC BioPharma, signed the amendment on behalf of the company.

Industry Context

Convertible notes are a common financing tool for biotech companies, especially those in early stages. The amendment reflects the need to balance the interests of the lender and the company, particularly in volatile market conditions. The inclusion of a floor price is a common protection for the lender.

Comparison to Industry Standards

• The use of a convertible note with a floor price is a common practice in biotech financing, similar to deals seen with companies like XOMA Corporation and Agenus Inc.
• The cash payment mechanism is less common but not unheard of, and is designed to compensate the lender if the conversion price is significantly lower than the market price, similar to some structured financings by companies like Sorrento Therapeutics.
• The warrant structure is also standard, with the number of shares and exercise price being typical for this type of financing, comparable to warrants issued by companies like Cassava Sciences.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The cash payment obligation could negatively impact the company's financial position.
• The amendment provides more certainty for Lind Global Fund II, LP.

Next Steps

• ABVC BioPharma needs to prepare for the shareholder meeting by April 17, 2024.
• ABVC BioPharma needs to monitor its stock price to assess the likelihood of the conversion price hitting the floor price and triggering the cash payment.

Key Dates

Keywords

convertible note, amendment, floor price, cash payment, Lind Global Fund II, securities purchase agreement, shareholder meeting, conversion price, warrant, ABVC BioPharma